Press release
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral
About this update from Anavex Life Sciences Corp.
[{"type":"text","content":"ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and continued long-term treatment of chronic Alzheimer’s disease Blarcamesine exhibited a favorable safety profile with no treatment-related deaths NEW YORK, April 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that over three years of continuous treatment with blarcamesine (ANAVEX®2-73) demonstrated significantly amelioration on clinical decline showing continued clinically and meaningful benefit for early Alzheimer’s disease patients. ATTENTION-AD (ANAVEX®2-73-AD-EP-004) trial result was presented at the AD/PDTM 2025 Conference. Continued blarcamesine treatment up to four (4) years demonstrated good comparative safety profile and no associated neuroimaging adverse events (no potentially fatal brain bleeding or brain swelling). There were no deaths related to the study drug. The ATTENTION-AD (ANAVEX®2-73-AD-EP-004) trial followed the 48-week ANAVEX®2-73-AD-004 double-blind (DB) clinical trial, lasting up to 192 weeks, with an open-label extension (OLE) treatment duration of 96 weeks for participants in Canada and Europe and up to 144 weeks for participants in Australia1 to evaluate the safety and tolerability of blarcamesine and long-term effects of blarcamesine on cognition and function in participants with early Alzheimer’s disease.2 Blarcamesine-treated patients continue to accrue benefit through up to 4 years, as measured by the clinical endpoints ADAS-Cog13 and ADCS-ADL. Delayed-start analysis of treatment with oral blarcamesine using the prespecified MMRM analysis method was significant, reflecting importance of early treatment initiation. Continued blarcamesine treatment—without interruption—is encouraged for more favorable clinical outcome that may indicate disease-modifying effect. “The long-term clinical ATTENTION-AD study results are very meaningful, demonstrating that diagnosing and...